연구동향 분석
박사

Development of Botanical Formulation, HX106N, for Improving Memory Functions and Analysis of Underlying Mechanisms : 기억력 개선 식물 소재 HX106N의 개발과 작용 원리 분석

이두석 2015년

논문상세정보
인용/피인용
' Development of Botanical Formulation, HX106N, for Improving Memory Functions and Analysis of Underlying Mechanisms : 기억력 개선 식물 소재 HX106N의 개발과 작용 원리 분석' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • alzheimer’s disease
  • amyloid β
  • dementia
  • hemeoxygenase-1
  • hx106n
  • neurodegenerative disease
  • oxidative stress
  • scopolamine
  • traditional korea medicine
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,157 0

0.0%

' Development of Botanical Formulation, HX106N, for Improving Memory Functions and Analysis of Underlying Mechanisms : 기억력 개선 식물 소재 HX106N의 개발과 작용 원리 분석' 의 참고문헌

  • Zhong XK, Li DC, Jiang JG. Identification and quality control of Chinesemedicine based on the fingerprint techniques. Curr Med Chem. 2009;16:3064-75.
  • Zhao GR, Xiang ZJ, Ye TX, Yuan YJ, Guo ZX. Antioxidant activities of Salviamiltiorrhiza and Panax notoginseng. Food Chem. 2006;99:767-74.
  • Zamani MR, Allen YS, Owen GP, Gray JA. Nicotine modulates the neurotoxiceffect of beta-amyloid protein(25-35)) in hippocampal cultures. Neuroreport.1997;8:513-7.
  • Yiannopoulou KG, Papageorgiou SG. Current and future treatments forAlzheimer's disease. Ther Adv Neurol Disord. 2013;6:19-33.
  • Yamada K, Nabeshima T. Animal models of Alzheimer's disease and evaluationof anti-dementia drugs. Pharmacol Ther. 2000;88:93-113.
  • Xie QW, Whisnant R, Nathan C. Promoter of the mouse gene encoding calciumindependentnitric oxide synthase confers inducibility by interferon gamma andbacterial lipopolysaccharide. J Exp Med. 1993;177:1779-84.
  • Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review ofthe basic science and clinical literature. Cold Spring Harb Perspect Med.2012;2:a006346.
  • Wilkinson BL, Landreth GE. The microglial NADPH oxidase complex as asource of oxidative stress in Alzheimer's disease. J Neuroinflammation.2006;3:30.
  • White KA, Marletta MA. Nitric-Oxide Synthase Is a Cytochrome-P-450 TypeHemoprotein. Biochemistry-Us. 1992;31:6627-31.
  • Wang Q, Wu J, Rowan MJ, Anwyl R. Beta-amyloid inhibition of long-termpotentiation is mediated via tumor necrosis factor. Eur J Neurosci.2005;22:2827-32.
  • Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure inAlzheimer's disease. Neuron. 2004;44:181-93.
  • Vodovotz Y, Bogdan C, Paik J, Xie QW, Nathan C. Mechanisms of suppressionof macrophage nitric oxide release by transforming growth factor beta. J ExpMed. 1993;178:605-13.
  • Vareille M, Rannou F, Thelier N, Glasser AL, de Sablet T, Martin C, Gobert AP.Heme oxygenase-1 is a critical regulator of nitric oxide production inenterohemorrhagic Escherichia coli-infected human enterocytes. J Immunol.2008;180:5720-6.
  • Uttara, B., Singh, A. V., Zamboni, P., Mahajan, R.T., Oxidative stress andneurodegenerative diseases: A review of upstream and downstreamAntioxidant therapeutic options. Curr. Neuropharmacol, 2009, 7, 65?74.
  • Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int JBiochem Cell Biol. 2005;37:289-305.
  • Tsoyi K, Kim HJ, Shin JS, Kim DH, Cho HJ, Lee SS, Ahn SK, Yun-Choi HS,Lee JH, Seo HG, Chang KC. HO-1 and JAK-2/STAT-1 signals are involved inpreferential inhibition of iNOS over COX-2 gene expression by newly? ? ? synthesized tetrahydroisoquinoline alkaloid, CKD712, in cells activated withlipopolysacchride. Cell Signal. 2008;20:1839-47.
  • Tran MH, Yamada K, Nabeshima T. Amyloid beta-peptide induces cholinergicdysfunction and cognitive deficits: a minireview. Peptides. 2002;23:1271-83.? ? ?
  • Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox regulation ofcell survival. Antioxid Redox Signal. 2008;10:1343-74.
  • Thies W, Bleiler L, Assoc As. 2013 Alzheimer's disease facts and figuresAlzheimer's Association. Alzheimers & Dementia. 2013;9:208-45.
  • Terry AV, Jr., Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer'sdisease-related cognitive deficits: recent challenges and their implications fornovel drug development. J Pharmacol Exp Ther. 2003;306:821-7.
  • Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month,randomized, placebo-controlled trial of galantamine in AD. The GalantamineUSA-10 Study Group. Neurology. 2000;54:2269-76.
  • Tanzi RE. Alzheimer's disease and related dementias: the road to intervention.Exp Gerontol. 2000;35:433-7.
  • Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloidhypothesis: a genetic perspective. Cell. 2005;120:545-55.
  • Tan S, Schubert D, Maher P. Oxytosis: A novel form of programmed cell death.Curr Top Med Chem. 2001;1:497-506.
  • Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the? ? ? presynaptic vesicle protein synaptophysin in hippocampus correlates withcognitive decline in Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:933-44.
  • Surh YJ, Kundu JK, Na HK. Nrf2 as a Master Redox Switch in Turning on theCellular Signaling Involved in the Induction of Cytoprotective Genes by SomeChemopreventive Phytochemicals. Planta Med. 2008;74:1526-39.
  • Stocker R, Yamamoto Y, Mcdonagh AF, Glazer AN, Ames BN. Bilirubin Is anAntioxidant of Possible Physiological Importance. Science. 1987;235:1043-6.
  • Son Y, Byun SJ, Pae HO. Involvement of heme oxygenase-1 expression inneuroprotection by piceatannol, a natural analog and a metabolite of resveratrol,against glutamate-mediated oxidative injury in HT22 neuronal cells. AminoAcids. 2013;45:393-401.
  • Sinha S, Lieberburg I. Cellular mechanisms of beta-amyloid production andsecretion. Proc Natl Acad Sci U S A. 1999;96:11049-53.
  • Schubert D, Piasecki D. Oxidative glutamate toxicity can be a component of theexcitotoxicity cascade. J Neurosci. 2001;21:7455-62.
  • Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H.Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl AcadSci U S A. 1995;92:1989-93.
  • Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R,Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M. Clinical trials and latestagedrug development for Alzheimer's disease: an appraisal from 1984 to 2014.J Intern Med. 2014;275:251-83.
  • Schipper HM, Cisse S, Stopa EG. Expression of heme oxygenase-1 in thesenescent and Alzheimer-diseased brain. Ann Neurol. 1995;37:758-68.
  • Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J,Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, MotterR, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, WogulisM, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuatesAlzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-7.
  • Sawle P, Foresti R, Mann BE, Johnson TR, Green CJ, Motterlini R. Carbonmonoxide-releasing molecules (CO-RMs) attenuate the inflammatory responseelicited by lipopolysaccharide in RAW264.7 murine macrophages. Brit JPharmacol. 2005;145:800-10.
  • Saura J, Tusell JM, Serratosa J. High-yield isolation of murine microglia by mild? ??? trypsinization. Glia. 2003;44:183-9.
  • Sattler R, Tymianski M. Molecular mechanisms of glutamate receptor-mediatedexcitotoxic neuronal cell death. Mol Neurobiol. 2001;24:107-29.
  • Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition.Nat Rev Neurosci. 2005;6:48-56.
  • Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M,Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B,Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, GrundmanM, Yuen E, Black R, Brashear HR. Two phase 3 trials of bapineuzumab in mildto-moderate Alzheimer's disease. N Engl J Med. 2014;370:322-33.
  • Ryter SW, Xi S, Hartsfield CL, Choi AM. Mitogen activated protein kinase(MAPK) pathway regulates heme oxygenase-1 gene expression by hypoxia invascular cells. Antioxid Redox Signal. 2002;4:587-92.
  • Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basicscience to therapeutic applications. Physiol Rev. 2006;86:583-650.
  • Rossler OG, Bauer I, Chung HY, Thiel G. Glutamate-induced cell death ofimmortalized murine hippocampal neurons: neuroprotective activity of hemeoxygenase-1, heat shock protein 70, and sodium selenite. Neurosci Lett.2004;362:253-7.
  • Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, StahelinHB, Hartman R, Gharabawi M. Efficacy and safety of rivastigmine in patientswith Alzheimer's disease: international randomised controlled trial. BMJ.1999;318:633-8.
  • Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, doubleblind,placebo-controlled trial of donepezil in patients with Alzheimer's disease.Donepezil Study Group. Neurology. 1998;50:136-45.
  • Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B,Walker D, McGeer P. Inflammation and Alzheimer's disease pathogenesis.Neurobiol Aging. 1996;17:681-6.
  • Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune systemassociatedantigens by cells of the human central nervous system: relationship tothe pathology of Alzheimer's disease. Neurobiol Aging. 1988;9:339-49.? ???
  • Rodriguez-Pascual F, Hausding M, Ihrig-Biedert I, Furneaux H, Levy AP,Forstermann U, Kleinert H. Complex contribution of the 3'-untranslated regionto the expressional regulation of the human inducible nitric-oxide synthase gene.Involvement of the RNA-binding protein HuR. J Biol Chem. 2000;275:26040-9.
  • Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine inmoderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-41.
  • Petersen RC. Mild cognitive impairment: transition between aging andAlzheimer's disease. Neurologia. 2000;15:93-101.
  • Pautz A, Linker K, Altenhofer S, Heil S, Schmidt N, Art J, Knauer S, Stauber R,Sadri N, Pont A, Schneider RJ, Kleinert H. Similar regulation of humaninducible nitric-oxide synthase expression by different isoforms of the RNAbindingprotein AUF1. J Biol Chem. 2009;284:2755-66.
  • Paschoud S, Dogar AM, Kuntz C, Grisoni-Neupert B, Richman L, Kuhn LC.Destabilization of interleukin-6 mRNA requires a putative RNA stem-loopstructure, an AU-rich element, and the RNA-binding protein AUF1. Mol CellBiol. 2006;26:8228-41.
  • Park SJ, Park DH, Kim DH, Lee S, Yoon BH, Jung WY, Lee KT, Cheong JH,Ryu JH. The memory-enhancing effects of Euphoria longan fruit extract in mice.? ??? J Ethnopharmacol. 2010;128:160-5.
  • Park J, Liu AY. JNK phosphorylates the HSF1 transcriptional activation domain:role of JNK in the regulation of the heat shock response. J Cell Biochem.2001;82:326-38.
  • Park J, Lee C. The encyclopedia of medicinal plants. Shinilbooks, Seoul.2000:363-4.
  • Panahian N, Yoshiura M, Maines MD. Overexpression of heme oxygenase-1 isneuroprotective in a model of permanent middle cerebral artery occlusion intransgenic mice. J Neurochem. 1999;72:1187-203.
  • Otterbein LE, Bach FH, Alam J, Soares M, Lu HT, Wysk M, Davis RJ, FlavellRA, Choi AMK. Carbon monoxide has anti-inflammatory effects involving themitogen-activated protein kinase pathway. Nat Med. 2000;6:422-8.
  • Na HK, Surh YJ. Transcriptional regulation via cysteine thiol modification: Anovel molecular strategy for chemoprevention and cytoprotection. MolCarcinogen. 2006;45:368-80.
  • Murphy TH, Schnaar RL, Coyle JT. Immature cortical neurons are uniquelysensitive to glutamate toxicity by inhibition of cystine uptake. Faseb J.1990;4:1624-33.
  • Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT. Glutamate toxicityin a neuronal cell line involves inhibition of cystine transport leading tooxidative stress. Neuron. 1989;2:1547-58.
  • Mukherjee PK, Kumar V, Mal M, Houghton PJ. Acetylcholinesterase inhibitorsfrom plants. Phytomedicine. 2007;14:289-300.
  • Minogue AM, Schmid AW, Fogarty MP, Moore AC, Campbell VA, Herron CE,Lynch MA. Activation of the c-Jun N-terminal kinase signaling cascademediates the effect of amyloid-beta on long term potentiation and cell death inhippocampus: a role for interleukin-1beta? J Biol Chem. 2003;278:27971-80.
  • Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects ofdonepezil against amyloid beta25-35 peptide-induced toxicity in mice involve aninteraction with the sigma1 receptor. Br J Pharmacol. 2006;149:998-1012.
  • Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL, DafreAL, Di Giunta G, Figueiredo CP, Takahashi RN, Campos MM, Calixto JB.Connecting TNF-alpha signaling pathways to iNOS expression in a mouse? ??? model of Alzheimer's disease: relevance for the behavioral and synaptic deficitsinduced by amyloid beta protein. J Neurosci. 2007;27:5394-404.
  • McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. CochraneDatabase Syst Rev. 2006:CD003154.
  • Maurice T, Lockhart BP, Privat A. Amnesia induced in mice by centrallyadministered beta-amyloid peptides involves cholinergic dysfunction. Brain Res.1996;706:181-93.
  • Mattson MP. Pathways towards and away from Alzheimer's disease. Nature.2004;430:631-9.
  • Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human corticalneurons vulnerable to excitotoxicity. J Neurosci. 1992;12:376-89.
  • Markesbery WR. The role of oxidative stress in Alzheimer disease. Arch Neurol.1999;56:1449-52.
  • Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of axonsby tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging.2003;24:1079-85.
  • LyonsCR,OrloffGJ,Cunningham JM.Molecularcloning and functionalexpression of an inducible nitric oxide synthase from a murinemacrophagecellline.JBiolChem.1992;267:6370-4.
  • Lu DY, Tsao YY, Leung YM, Su KP. Docosahexaenoic Acid SuppressesNeuroinflammatory Responses and Induces Heme Oxygenase-1 Expression in? ? ? BV-2 Microglia: Implications of Antidepressant Effects for Omega-3 Fatty Acids.Neuropsychopharmacol. 2010;35:2238-48.
  • Lockhart BP, Benicourt C, Junien JL, Privat A. Inhibitors of free radicalformation fail to attenuate direct beta-amyloid25-35 peptide-mediatedneurotoxicity in rat hippocampal cultures. J Neurosci Res. 1994;39:494-505.
  • Liu J, Wang LN, Tian JZ. Recognition of dementia in ancient China. Neurobiol? ??? Aging. 2012;33:2948 e11-3.
  • Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerativediseases: mechanisms and strategies for therapeutic intervention. J PharmacolExp Ther. 2003;304:1-7.
  • Li Y, Maher P, Schubert D. Requirement for cGMP in nerve cell death caused byglutathione depletion. J Cell Biol. 1997;139:1317-24.
  • Li Y, Maher P, Schubert D. A role for 12-lipoxygenase in nerve cell death causedby glutathione depletion. Neuron. 1997;19:453-63.
  • Lee SA, Kim EY, Jeon WK, Woo CH, Choe J, Han S, Kim BC. The inhibitoryeffect of raloxifene on lipopolysaccharide-induced nitric oxide production inRAW264.7 cells is mediated through a ROS/p38 MAPK/CREB pathway to theup-regulation of heme oxygenase-1 independent of estrogen receptor. Biochimie.2011;93:168-74.? ? ?
  • Lee PJ, Camhi SL, Chin BY, Alam J, Choi AM. AP-1 and STAT mediatehyperoxia-induced gene transcription of heme oxygenase-1. Am J Physiol LungCell Mol Physiol. 2000;279:L175-82.
  • Lee J, Kim D, Choi J, Choi H, Ryu JH, Jeong J, Park EJ, Kim SH, Kim S.Dehydrodiconiferyl alcohol isolated from Cucurbita moschata shows anti? ??? adipogenic and anti-lipogenic effects in 3T3-L1 cells and primary mouseembryonic fibroblasts. J Biol Chem. 2012;287:8839-51.
  • Le WD, Xie WJ, Appel SH. Protective role of heme oxygenase-1 in oxidativestress-induced neuronal injury. J Neurosci Res. 1999;56:652-8.
  • Le W, Xie W, Appel SH. Protective role of heme oxygenase-1 in oxidativestress-induced neuronal injury. J Neurosci Res. 1999;56:652-8.
  • Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL,Weiner MW, Jagust WJ. Associations between cognitive, functional, and FDGPETmeasures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207-18.
  • Kweon MN, Fujihashi K, VanCott JL, Higuchi K, Yamamoto M, McGhee JR,Kiyono H. Lack of orally induced systemic unresponsiveness in IFN-gammaknockout mice. J Immunol. 1998;160:1687-93.
  • Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. Effect of donepezil hydrochloride(E2020) on basal concentration of extracellular acetylcholine in thehippocampus of rats. Eur J Pharmacol. 1999;380:101-7.
  • Korhonen R, Kankaanranta H, Lahti A, Lahde M, Knowles RG, Moilanen E. Bidirectionaleffects of the elevation of intracellular calcium on the expression ofinducible nitric oxide synthase in J774 macrophages exposed to low and to highconcentrations of endotoxin. Biochem J. 2001;354:351-8.
  • Korczyn AD. Why have we failed to cure Alzheimer's disease? J Alzheimers Dis.2012;29:275-82.
  • Koh K, Cha Y, Kim S, Kim J. tBHQ inhibits LPS-induced microglial activationvia Nrf2-mediated suppression of p38 phosphorylation. Biochem Biophys ResCommun. 2009;380:449-53.
  • Klinkenberg I, Blokland A. The validity of scopolamine as a pharmacologicalmodel for cognitive impairment: a review of animal behavioral studies. NeurosciBiobehav Rev. 2010;34:1307-50.
  • Kim KW, Park JH, Kim MH, Kim MD, Kim BJ, Kim SK, Kim JL, Moon SW,Bae JN, Woo JI, Ryu SH, Yoon JC, Lee NJ, Lee DY, Lee DW, Lee SB, Lee JJ,Lee JY, Lee CU, Chang SM, Jhoo JH, Cho MJ. A nationwide survey on theprevalence of dementia and mild cognitive impairment in South Korea. JAlzheimers Dis. 2011;23:281-91.
  • Kim JS, Narula AS, Jobin C. Salvia miltiorrhiza water-soluble extract, but not itsconstituent salvianolic acid B, abrogates LPS-induced NF-kappa B signalling inintestinal epithelial cells. Clin Exp Immunol. 2005;141:288-97.
  • Kim HJ, Moon KD, Oh SY, Kim SP, Lee SR. Ether fraction of methanol extractsof Gastrodia elata, a traditional medicinal herb, protects against kainic acidinducedneuronal damage in the mouse hippocampus. Neurosci Lett.2001;314:65-8.
  • Kim D, Kim SH, Park EJ, Kang CY, Cho SH, Kim S. Anti-allergic effects ofPG102, a water-soluble extract prepared from Actinidia arguta, in a murineovalbumin-induced asthma model. Clin Exp Allergy. 2009;39:280-9.
  • Kim D, Choi J, Kim MJ, Kim SH, Cho SH, Kim S. Reconstitution of antiallergicactivities of PG102 derived from Actinidia arguta by combiningsynthetic chemical compounds. Exp Biol Med (Maywood). 2013;238:631-40.
  • Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T,Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloidtoxicity. Ann Neurol. 1997;42:159-63.
  • Kang B, Ko E, No S, Park Y, Seo B, Seo Y. Herbology2000.
  • Juurlink BH, Schultke E, Hertz L. Glutathione release and catabolism duringenergy substrate restriction in astrocytes. Brain Res. 1996;710:229-33.
  • Juan SH, Cheng TH, Lin HC, Chu YL, Lee WS. Mechanism of concentrationdependentinduction of heme oxygenase-1 by resveratrol in human aorticsmooth muscle cells. Biochem Pharmacol. 2005;69:41-8.
  • Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress andneurodegenerative disorders. Mol Cell Biochem. 2010;345:91-104.
  • Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P,Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, ThiesWH. Appropriate Use Criteria for Amyloid PET: A Report of the AmyloidImaging Task Force, the Society of Nuclear Medicine and Molecular Imaging,and the Alzheimer's Association. Journal of Nuclear Medicine. 2013;54:476-90.
  • Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, ChishtiMA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, BergeronC, Fraser PE, St George-Hyslop P, Westaway D. A beta peptide immunizationreduces behavioural impairment and plaques in a model of Alzheimer's disease.Nature. 2000;408:979-82.
  • Immenschuh S, Ramadori G. Gene regulation of heme oxygenase-1 as a? ? ? therapeutic target. Biochem Pharmacol. 2000;60:1121-8.
  • Imbimbo BP, Giardina GA. gamma-secretase inhibitors and modulators for thetreatment of Alzheimer's disease: disappointments and hopes. Curr Top MedChem. 2011;11:1555-70.
  • Hur J, Lee P, Moon E, Kang I, Kim SH, Oh MS, Kim SY. Neurite outgrowthinduced by spicatoside A, a steroidal saponin, via the tyrosine kinase A receptorpathway. Eur J Pharmacol. 2009;620:9-15.
  • Hooper NM, Turner AJ. The search for alpha-secretase and its potential as atherapeutic approach to Alzheimer s disease. Curr Med Chem. 2002;9:1107-19.
  • Ho YS, Magnenat JL, Gargano M, Cao J. The nature of antioxidant defensemechanisms: a lesson from transgenic studies. Environ Health Perspect.1998;106 Suppl 5:1219-28.
  • Hirai S. Alzheimer disease: current therapy and future therapeutic strategies.Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S11-7.
  • Hill-Kapturczak N, V T, Liu FY, Nick HS, Agarwal A. Mechanism of hemeoxygenase-1 gene induction by curcumin in human renal proximal tubule cells.Am J Physiol-Renal. 2001;281:F851-F9.
  • Hey J, Koelsch G, Bilcer G, Jacobs A, Tolar M, Tang J, Ghosh A, Hsu H, editors.Single dose administration of the ??-secretase inhibitor CTS21166 (ASP1702)reduces plasma A??40 in human subjects. International Conference on? ????Alzheimer ?s Disease (ICAD), Chicago, IL; 2008.
  • Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. State-specificprojections through 2025 of Alzheimer disease prevalence. Neurology.2004;62:1645.
  • Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci1997;20:154-9.
  • Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer sdisease: progress and problems on the road to therapeutics.Science 2002;297:353?6.
  • Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology ofAlzheimer's disease. Trends Pharmacol Sci. 1991;12:383-8.
  • Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L,Selkoe DJ. The Swedish mutation causes early-onset Alzheimer's disease bybeta-secretase cleavage within the secretory pathway. Nat Med. 1995;1:1291-6.? ???
  • Grossman H, Bergmann C, Parker S. Dementia: a brief review. Mt Sinai J Med.2006;73:985-92.
  • Geng Y, Lotz M. Increased intracellular Ca2+ selectively suppresses IL-1-induced NO production by reducing iNOS mRNA stability. J Cell Biol.1995;129:1651-7.
  • Geller DA, Lowenstein CJ, Shapiro RA, Nussler AK, Di Silvio M, Wang SC,Nakayama DK, Simmons RL, Snyder SH, Billiar TR. Molecular cloning andexpression of inducible nitric oxide synthase from human hepatocytes. Proc NatlAcad Sci U S A. 1993;90:3491-5.
  • Gandhi S, Abramov AY. Mechanism of oxidative stress in neurodegeneration.Oxid Med Cell Longev. 2012;2012:428010.
  • Galea E, Reis DJ, Feinstein DL. Cloning and expression of inducible nitric oxide? ? ? synthase from rat astrocytes. J Neurosci Res. 1994;37:406-14.
  • Fukui M, Song JH, Choi J, Choi HJ, Zhu BT. Mechanism of glutamate-inducedneurotoxicity in HT22 mouse hippocampal cells. Eur J Pharmacol. 2009;617:1-11.
  • Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis ofAlzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry.1999;66:137-47.
  • Drechsler Y, Dolganiuc A, Norkina O, Romics L, Li W, Kodys K, Bach FH,Mandrekar P, Szabo G. Heme oxygenase-1 mediates the anti-inflammatoryeffects of acute alcohol on IL-10 induction involving p38 MAPK activation inmonocytes. J Immunol. 2006;177:2592-600.
  • Dore S, Takahashi M, Ferris CD, Zakhary R, Hester LD, Guastella D, SnyderSH. Bilirubin, formed by activation of heme oxygenase-2, protects neuronsagainst oxidative stress injury (vol 96, pg 2445, 1999). P Natl Acad Sci USA.1999;96:10944-.
  • Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K,Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R. Phase 3 trials ofsolanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med.2014;370:311-21.
  • Dinkova-Kostova AT, Talalay P. Direct and indirect antioxidant properties ofinducers of cytoprotective proteins. Mol Nutr Food Res. 2008;52:S128-S38.
  • Dean JL, Wait R, Mahtani KR, Sully G, Clark AR, Saklatvala J. The 3'untranslated region of tumor necrosis factor alpha mRNA is a target of themRNA-stabilizing factor HuR. Mol Cell Biol. 2001;21:721-30.? ? ??
  • Davis JB, Maher P. Protein kinase C activation inhibits glutamate-inducedcytotoxicity in a neuronal cell line. Brain Res. 1994;652:169-73.
  • Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerativedisorders. Science. 1993;262:689-95.
  • Costantini LC, Barr LJ, Vogel JL, Henderson ST. Hypometabolism as atherapeutic target in Alzheimer's disease. BMC Neurosci. 2008;9 Suppl 2:S16.
  • Choi J, Lee J, Kim SH, Kim J, Kim S. PG201 downregulates the production ofnitrite by upregulating heme oxygenase-1 expression through the control ofphosphatidylinositol 3-kinase and NF-E2-related factor 2. Nitric Oxide.2013;33:42-55.
  • Choi J, Kim SH, Kim S. Suppressive effects of PG201, an antiarthritic botanicalformulation, on lipopolysaccharide-induced inflammatory mediators inRaw264.7 cells. Exp Biol Med (Maywood). 2012;237:499-508.
  • Cho MJ, Lee JY, Kim BS, Lee HW, Sohn JH. Prevalence of the major mentaldisorders among the Korean elderly. J Korean Med Sci. 2011;26:1-10.
  • Chen K, Gunter K, Maines MD. Neurons overexpressing heme oxygenase-1resist oxidative stress-mediated cell death. J Neurochem. 2000;75:304-13.
  • Carter AB, Knudtson KL, Monick MM, Hunninghake GW. The p38 mitogenactivatedprotein kinase is required for NF-kappaB-dependent gene expression.The role of TATA-binding protein (TBP). J Biol Chem. 1999;274:30858-63.
  • Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A.Identification of a common nucleotide sequence in the 3'-untranslated region ofmRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A.1986;83:1670-4.
  • Camhi SL, Alam J, Otterbein L, Sylvester SL, Choi AM. Induction of hemeoxygenase-1 gene expression by lipopolysaccharide is mediated by AP-1activation. Am J Respir Cell Mol Biol. 1995;13:387-98.
  • Calkins MJ, Johnson DA, Townsend JA, Vargas MR, Dowell JA, Williamson TP,Kraft AD, Lee JM, Li J, Johnson JA. The Nrf2/ARE pathway as a potentialtherapeutic target in neurodegenerative disease. Antioxid Redox Signal.2009;11:497-508.
  • Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M. Neuron loss in APP transgenicmice. Nature. 1998;395:755-6.
  • Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer'sdisease: therapeutic implications. CNS Drugs. 2003;17:641-52.
  • Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloidbeta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's diseasebrain contribute to neuronal death. Neurobiol Aging. 2002;23:655-64.
  • Busciglio J, Lorenzo A, Yeh J, Yankner BA. beta-amyloid fibrils induce tauphosphorylation and loss of microtubule binding. Neuron. 1995;14:879-88.
  • Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitricoxide, glutamate, and mitochondria. Mol Neurobiol. 2003;27:325-55.
  • Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci.2001;58:266-77.
  • Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering themolecular mechanisms. Nat Rev Neurosci. 2007;8:57-69.
  • Benzi G, Moretti A. Is there a rationale for the use of acetylcholinesteraseinhibitors in the therapy of Alzheimer's disease? Eur J Pharmacol. 1998;346:1-13.
  • Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, Alam J,Motterlini R. Curcumin activates the haem oxygenase-1 gene via regulation ofNrf2 and the antioxidant-responsive element. Biochem J. 2003;371:887-95.
  • Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW,Vercellotti GM. Ferritin: a cytoprotective antioxidant strategem of endothelium.? ? ? J Biol Chem. 1992;267:18148-53.
  • Assoc A. Alzheimer's Association Report 2011 Alzheimer's disease facts andfigures. Alzheimers & Dementia. 2011;7:208-44.
  • Alfirevic A, Mills T, Carr D, Barratt BJ, Jawaid A, Sherwood J, Smith JC,? ??? Tugwood J, Hartkoorn R, Owen A, Park KB, Pirmohamed M. Tacrine-inducedliver damage: an analysis of 19 candidate genes. Pharmacogenet Genomics.2007;17:1091-100.
  • Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL. Nrf2, aCap'n'Collar transcription factor, regulates induction of the heme oxygenase-1gene. J Biol Chem. 1999;274:26071-8.
  • Alam J, Den Z. Distal AP-1 binding sites mediate basal level enhancement andTPA induction of the mouse heme oxygenase-1 gene. J Biol Chem.1992;267:21894-900.
  • Alam J, Cook JL. Transcriptional regulation of the heme oxygenase-1 gene viathe stress response element pathway. Curr Pharm Design. 2003;9:2499-511.
  • Alam J, Cook JL. How many transcription factors does it take to turn on theheme oxygenase-1 gene? Am J Resp Cell Mol. 2007;36:166-74.
  • Alam J, Camhi S, Choi AM. Identification of a second region upstream of themouse heme oxygenase-1 gene that functions as a basal level and inducerdependenttranscription enhancer. J Biol Chem. 1995;270:11977-84.
  • Alam J, Cai J, Smith A. Isolation and characterization of the mouse hemeoxygenase-1 gene. Distal 5' sequences are required for induction by heme orheavy metals. J Biol Chem. 1994;269:1001-9.
  • Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci.2004;75:639-53.
  • Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR,Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS,Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL,O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, ShenY, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, WalkerD, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation andAlzheimer's disease. Neurobiol Aging. 2000;21:383-421.